Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmacyclics Gets “Refuse To File” Letter On Xcytrin

This article was originally published in The Pink Sheet Daily

Executive Summary

Company had hoped for priority review when it submitted its NDA for treatment of brain metastases from non-small cell lung cancer in December.
Advertisement

Related Content

Pharmacyclics’ Xcytrin Gets FDA “Not Approvable” For NSCLC Patients With Brain Metastases
Pharmacyclics’ Xcytrin Gets FDA “Not Approvable” For NSCLC Patients With Brain Metastases
Pharmacyclics Taps Little-Used Regulatory Pathway For Xcytrin NDA
Pharmacyclics Taps Little-Used Regulatory Pathway For Xcytrin NDA
Pharmacyclics Eyes Priority Review For NSCLC Treatment
Pharmacyclics Eyes Priority Review For NSCLC Treatment
Merck’s Zolinza Approved For Rare Skin Cancer
Pharmacyclics Plans Xcytrin NDA Based On New Data Analysis

Topics

Advertisement
UsernamePublicRestriction

Register

PS065670

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel